BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$91.24

Market cap

$17.19B

P/E Ratio

118.49

Dividend/share

N/A

EPS

$0.77

Enterprise value

$17.49B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
The net income has surged by 75% year-on-year and by 47% since the previous quarter
Biomarin Pharmaceutical's EPS has surged by 71% YoY and by 48% QoQ
BMRN's quick ratio has dropped by 55% year-on-year and by 51% since the previous quarter

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
188.37M
Market cap
$17.19B
Enterprise value
$17.49B
Valuations
Price to book (P/B)
3.51
Price to sales (P/S)
7.43
EV/EBIT
105
EV/EBITDA
65.1
EV/Sales
7.57
Earnings
Revenue
$2.31B
EBIT
$166.54M
EBITDA
$268.62M
Free cash flow
$28.43M
Per share
EPS
$0.77
Free cash flow per share
$0.15
Book value per share
$26.02
Revenue per share
$12.28
TBVPS
$33.26
Balance sheet
Total assets
$6.76B
Total liabilities
$1.86B
Debt
$1.09B
Equity
$4.9B
Working capital
$1.79B
Liquidity
Debt to equity
0.22
Current ratio
2.54
Quick ratio
1.46
Net debt/EBITDA
1.12
Margins
EBITDA margin
11.6%
Gross margin
78.1%
Net margin
6.4%
Operating margin
5.2%
Efficiency
Return on assets
2.3%
Return on equity
3.1%
Return on invested capital
2.9%
Return on capital employed
3%
Return on sales
7.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
1.41%
1 week
2.78%
1 month
-1.93%
1 year
-11.57%
YTD
-5.37%
QTD
-5.37%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.31B
Gross profit
$1.8B
Operating income
$119.38M
Net income
$147.02M
Gross margin
78.1%
Net margin
6.4%
The net income has surged by 75% year-on-year and by 47% since the previous quarter
The net margin has soared by 52% year-on-year and by 42% since the previous quarter
The operating income has increased by 31% since the previous quarter and by 10% year-on-year
Biomarin Pharmaceutical's operating margin has increased by 27% from the previous quarter but it has decreased by 3.7% YoY

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
118.49
P/B
3.51
P/S
7.43
EV/EBIT
105
EV/EBITDA
65.1
EV/Sales
7.57
Biomarin Pharmaceutical's EPS has surged by 71% YoY and by 48% QoQ
BMRN's P/E is 30% below its last 4 quarters average of 170.1
The stock's price to book (P/B) is 14% less than its 5-year quarterly average of 4.1 and 5% less than its last 4 quarters average of 3.7
The equity has grown by 7% YoY and by 2.4% from the previous quarter
The revenue has grown by 15% YoY and by 3.4% from the previous quarter
BMRN's price to sales (P/S) is 12% less than its 5-year quarterly average of 8.4 and 7% less than its last 4 quarters average of 8.0

Efficiency

How efficient is Biomarin Pharmaceutical business performance
BMRN's return on assets has surged by 64% year-on-year and by 44% since the previous quarter
The ROE has soared by 63% YoY and by 48% from the previous quarter
Biomarin Pharmaceutical's ROIC has increased by 38% YoY and by 32% from the previous quarter
Biomarin Pharmaceutical's return on sales has increased by 31% QoQ and by 24% YoY

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
BMRN's quick ratio has dropped by 55% year-on-year and by 51% since the previous quarter
The company's current ratio has shrunk by 51% YoY and by 49% QoQ
The debt is 78% smaller than the equity
BMRN's debt to equity is down by 8% year-on-year and by 4.3% since the previous quarter
The equity has grown by 7% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.